These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 18613886)

  • 1. Prevention and treatment of glucocorticoid-induced osteoporosis in daily dermatologic practice.
    Vermaat H; Kirtschig G
    Int J Dermatol; 2008 Jul; 47(7):737-42. PubMed ID: 18613886
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Therapy of glucocorticoid induced osteoporosis].
    Arazzi M; Di Fulvio G; Di Pietro LO; Grabocka X; Longo MO; Micioni G; Pezzutto A; Piscitani L; Schiazza A; Silvestri S; Vigilante G; Amoroso L; Bonomini M
    G Ital Nefrol; 2017 Dec; 34(Nov-Dec):. PubMed ID: 29207221
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Secondary osteoporosis: underlying disease and the risk for glucocorticoid-induced osteoporosis.
    Boling EP
    Clin Ther; 2004 Jan; 26(1):1-14. PubMed ID: 14996513
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Glucocorticoid induced osteoporosis].
    Lange U; Müller-Ladner U
    Orthopade; 2007 Apr; 36(4):381-8; quiz 389-90. PubMed ID: 17665509
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Active vitamin D3 therapy for gulucocorticoid-induced osteoporosis].
    Nakayama H
    Clin Calcium; 2006 Jul; 16(7):1201-7. PubMed ID: 16816482
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How to prevent glucocorticoid-induced osteoporosis.
    Dore RK
    Cleve Clin J Med; 2010 Aug; 77(8):529-36. PubMed ID: 20682515
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Current topics over updating guidelines on the management and treatment of glucocorticoid-induced osteoporosis].
    Suzuki Y
    Clin Calcium; 2014 Mar; 24(3):417-24. PubMed ID: 24576939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bisphosphonates and glucocorticoid-induced osteoporosis: cons.
    Lems WF; Saag K
    Endocrine; 2015 Aug; 49(3):628-34. PubMed ID: 26041376
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Suggested rationale for prevention and treatment of glucocorticoid-induced bone loss in dermatologic patients.
    Yosipovitch G; Hoon TS; Leok GC
    Arch Dermatol; 2001 Apr; 137(4):477-81. PubMed ID: 11295929
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Glucocorticoid-induced osteoporosis and rheumatic diseases. Pathogenesis, prevention and treatment].
    Di Munno O; Delle Sedie A
    Reumatismo; 2006; 58(1):11-21. PubMed ID: 16639483
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging consensus on prevention and treatment of glucocorticoid-induced osteoporosis.
    Compston JE
    Curr Rheumatol Rep; 2007 Apr; 9(1):78-84. PubMed ID: 17437672
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Glucocorticoid induced osteoporosis in childhood: prophylaxis and treatment].
    Tanaka H
    Clin Calcium; 2009 Apr; 19(4):569-73. PubMed ID: 19329838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis.
    Arthritis Rheum; 2001 Jul; 44(7):1496-503. PubMed ID: 11465699
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Review of new guidelines for the management of glucocorticoid induced osteoporosis.
    Venuturupalli SR; Sacks W
    Curr Osteoporos Rep; 2013 Dec; 11(4):357-64. PubMed ID: 24114241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Glucocorticoid-induced osteoporosis : treatment update].
    Soen S
    Clin Calcium; 2012 Feb; 22(2):229-35. PubMed ID: 22298077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence-based guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis: a consensus document of the Belgian Bone Club.
    Devogelaer JP; Goemaere S; Boonen S; Body JJ; Kaufman JM; Reginster JY; Rozenberg S; Boutsen Y
    Osteoporos Int; 2006 Jan; 17(1):8-19. PubMed ID: 16217586
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention and treatment of glucocorticoid-induced osteoporosis.
    Doga M; Mazziotti G; Bonadonna S; Patelli I; Bilezikian JP; Canalis E; Giustina A
    J Endocrinol Invest; 2008 Jul; 31(7 Suppl):53-8. PubMed ID: 18791353
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect on bone turnover markers of once-yearly intravenous infusion of zoledronic acid versus daily oral risedronate in patients treated with glucocorticoids.
    Devogelaer JP; Sambrook P; Reid DM; Goemaere S; Ish-Shalom S; Collette J; Su G; Bucci-Rechtweg C; Papanastasiou P; Reginster JY
    Rheumatology (Oxford); 2013 Jun; 52(6):1058-69. PubMed ID: 23365149
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of glucocorticoid-induced low bone mineral density in children: a systematic review.
    Jayasena A; Atapattu N; Lekamwasam S
    Int J Rheum Dis; 2015 Mar; 18(3):287-93. PubMed ID: 25923606
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of risk and use of prophylaxis for glucocorticoidinduced-osteoporosis among dermatologists in the Pacific Northwest: a survey study.
    Notaro E; Fett N; Shinohara MM
    Dermatol Online J; 2017 Sep; 23(9):. PubMed ID: 29469715
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.